Antibody–drug conjugates in cancer and beyond: progress, promise, and perspectives

2025/06/10 by Victor S. Goldmacher · 1 voice
Medicine · #HER2/EGFR in Cancer Research #Monoclonal and Polyclonal Antibodies Research #Cancer Treatment and Pharmacology

paper · pdf · doi:10.1093/abt/tbaf013

openalex publication_date 2025/06/10 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Abstract

Antibody-drug conjugates (ADCs) are transforming cancer therapy by combining antibody specificity with potent cytotoxic agents, enabling targeted tumor cell killing while minimizing systemic toxicity. This special collection of Antibody Therapeutics presents a wide overview of recent advances in ADC research and development. Topics include targeting strategies, antibody formats, innovative payloads and bispecific apoptosis triggers, formulation strategies, toxicity profiling, and conjugation technologies. Together, these contributions reflect the rapid evolution of the ADC field and point toward safer, more effective therapies for cancer and beyond.

Citations

• Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate
• A review of conjugation technologies for antibody drug conjugates

Discussions

• @antibodytx.bsky.social is happy to announce the launch of the special collection "Antibody-Drug Conjugates in Cancer and Beyond", with this editorial written by Dr. Victor Goldmacher: doi.org/10.109 [bsky, 1 points, 0 comments]

Related

• The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
• Antibody–Drug Conjugates for Cancer Treatment
• Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers
• Antibody–drug conjugates in breast cancer
• Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate